Theriva Biologics (TOVX)
XASE:TOVX
Want to see TOVX full AI Analyst Report?
TOVX Stock Chart & Stats
$0.20
-$0.06(-3.70%)
At close: 4:00 PM EST
$0.20
-$0.06(-3.70%)
Day’s Range― - ―
52-Week Range$0.16 - $1.47
Previous CloseN/A
Volume37.66K
Average Volume (3M)8.88M
Market Cap
$16.46M
Enterprise Value$1.35M
Total Cash (Recent Filing)$13.06M
Total Debt (Recent Filing)$2.63M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 19, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.85
Shares Outstanding45,892,670
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-50.01
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$2.50Price Target Upside1150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.24
Revenue Forecast (FY)$29.37M
Bulls Say, Bears Say
Bulls Say
Capital-efficient Development PlanManagement's plan for a small dose-optimization study is a capital-efficient, de-risking step that could preserve cash and make a later pivotal trial or partnership more attractive.
Clinical Efficacy SignalsVIRAGE study produced encouraging signals and analyses indicate that more frequent dosing could improve survival, supporting confidence in a refined dosing strategy for a pivotal trial.
Regulatory FeedbackPositive feedback from an FDA end-of-phase 2 meeting aligns on a Phase 3 design that closely follows the earlier study, reducing regulatory and design risk for a larger trial.
Bears Say
Analyst Uncertainty On Trial FinancingAnalyst's recommendation remains Hold pending a finalized Phase 3 protocol and clearer plans for trial financing, which could damp investor enthusiasm until details are resolved.
Dosing Variability RiskVariability in dosing during earlier trials weakened confidence in the survival results and creates uncertainty about the optimal dosing approach for a larger trial.
Funding ShortfallReported cash resources appear limited relative to the expected needs of a large Phase 3 trial, making additional financing or a strategic partnership likely necessary.
Theriva Biologics News
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $0.16 and its highest was $1.47 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $16.46M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is May 19, 2026 which is in 17 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Mar 12, 2026. The company reported $1.85 earnings per share for the quarter, beating the consensus estimate of -$0.435 by $2.285.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.05.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 45,892,670 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of $1.85 in its last earnings report, beating expectations of -$0.435. Following the earnings report the stock price went up 1.685%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
TOVX Stock 12 Month Forecast
Average Price Target
$2.50
▲(1150.00% Upside)
Technical Analysis
Ownership Overview
0.57%
Insiders
0.51% Mutual Funds
0.54% Other Institutional Investors
97.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---